Summary
Unable to assess label adherence: the prompt provided multiple non-label product-identification/general drug-formulation claims, but the evaluation was not grounded in any actual FDA label excerpt text covering these specific claims (dose frequency, IR/ER dosing frequency, imprint/color/shape variability, pharmacy label/NDC confirmation, or third-party patent tracker statements). As a result, most claims are unsupported by the supplied label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Generic Seroquel is quetiapine.
No supplied FDA label excerpt addresses generic-product equivalence statements.
Generic Seroquel is sold by different manufacturers under the generic name or a brand-like name chosen by the company.
No supplied FDA label excerpt addresses marketing-naming practices for generics.
Generic Seroquel tablets or capsules can vary in appearance, including imprint codes, shapes, colors, and packaging, due to different manufacturers.
No supplied FDA label excerpt addresses appearance variability across manufacturers.
The most reliable way to identify generic Seroquel is the tablet/capsule imprint plus the strength on the label.
No supplied FDA label excerpt provides identification guidance based on imprint.
Different generic manufacturers make quetiapine tablets that can differ in color.
No supplied FDA label excerpt addresses color differences across manufacturers.
Different generic manufacturers make quetiapine tablets that can differ in shape.
No supplied FDA label excerpt addresses shape differences across manufacturers.
Different generic manufacturers make quetiapine tablets that can differ in imprint.
No supplied FDA label excerpt addresses imprint differences across manufacturers.
Different generic manufacturers make quetiapine tablets that can differ in release version (immediate vs extended).
No supplied FDA label excerpt addresses release-version product manufacturing differences.
Quetiapine has immediate-release and extended-release formulations.
No supplied FDA label excerpt explicitly supports the existence of both IR and ER formulations.
Quetiapine immediate-release is often dosed more than once daily.
No supplied FDA label excerpt provides dosing-frequency statements for immediate-release.
Quetiapine extended-release is often dosed once daily.
No supplied FDA label excerpt provides dosing-frequency statements for extended-release.
The pharmacy label should indicate whether the medication is quetiapine immediate-release or quetiapine extended-release.
No supplied FDA label excerpt provides pharmacy labeling/dispensing instructions about IR vs ER.
Extended-release tablets are often shaped and stamped differently than immediate-release.
No supplied FDA label excerpt supports differences in shape/stamping between IR and ER.
If the imprint, color, or strength does not match what the bottle says, the pill should not be identified based on appearance.
No supplied FDA label excerpt provides pill-identification safety instructions.
Checking the bottle label includes verifying the exact strength and whether the medication is immediate-release or extended-release.
No supplied FDA label excerpt provides such checklist-style dispensing/verification guidance.
If there is a mismatch, a pharmacy can confirm the exact product by NDC.
No supplied FDA label excerpt mentions NDC-based confirmation procedures.
DrugPatentWatch tracks patents and regulatory/exclusivity history tied to branded and generic versions of medicines.
No supplied FDA label excerpt supports statements about a third-party service’s tracking scope.
DrugPatentWatch can help explain why different manufacturers enter over time.
No supplied FDA label excerpt supports claims about how a third-party tracker can explain manufacturer entry timing.
Contradictions
Important Omissions
No FDA label-supported content was provided that addresses the label’s boxed warning and warnings/precautions (e.g., increased mortality in elderly patients with dementia-related psychosis; suicidality context) or other required safety information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The audited claims primarily relate to product appearance/identification and dosing frequency for IR vs ER, but these are unsupported by the supplied label excerpts. Unsupported dosing-frequency/IR-vs-ER identification guidance could lead to incorrect use if treated as label-accurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the supplied FDA label excerpts; the excerpts do not cover IR/ER existence, dosing frequency, pill identification by imprint/appearance, pharmacy verification procedures (including NDC), or third-party patent tracker statements.
Suggested Improvement
Limit statements to topics explicitly supported by the provided label excerpts (5.1 increased mortality in elderly with dementia-related psychosis; 5.2 suicidality warning context; 5.3 cerebrovascular adverse reactions context; 8.4 pediatric limitations; 8.5 geriatric dosing/monitoring considerations). Remove or rephrase unsupported claims about IR vs ER dosing frequency and product identification by imprint/color/shape, unless the corresponding FDA label sections are provided.